|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Christiansen JJ: Reassessing epithelial to
mesenchymal transition as a prerequisite for carcinoma invasion and
metastasis. Cancer Res. 66:8319–8326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laoukili J, Kooistra MRH, Brás A, et al:
FoxM1 is required for execution of the mitotic programme and
chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang DK, Son CH, Lee SK, Choi PJ, Lee KE
and Roh MS: Forkhead box M1 expression in pulmonary squamous cell
carcinoma: correlation with clinicopathologic features and its
prognostic significance. Hum Pathol. 40:464–470. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kretschmer C, Sterner-Kock A, Siedentopf
F, Schoenegg W, Schlag PM and Kemmner W: Identification of early
molecular markers for breast cancer. Mol Cancer. 10:152011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kalin TV, Wang IC, Ackerson TJ, Major ML,
Detrisac CJ, Kalinichenko VV, Lyubimov A and Costa RH: Increased
levels of the FoxM1 transcription factor accelerate development and
progression of prostate carcinomas in both TRAMP and LADY
transgenic mice. Cancer Res. 66:1712–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun HC, Li M, Lu JL, et al: Overexpression
of Forkhead box M1 protein associates with aggressive tumor
features and poor prognosis of hepatocellular carcinoma. Oncol Rep.
25:1533–1539. 2011.PubMed/NCBI
|
|
9
|
Cancer Genome Atlas Research Network.
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar
|
|
10
|
Green MR, Aya-Bonilla C, Gandhi MK, et al:
Integrative genomic profiling reveals conserved genetic mechanisms
for tumorigenesis in common entities of non-Hodgkin’s lymphoma.
Genes Chromosomes Cancer. 50:313–326. 2011.PubMed/NCBI
|
|
11
|
Huynh KM, Soh JW, Dash R, Sarkar D, Fisher
PB and Kang D: FOXM1 expression mediates growth suppression during
terminal differentiation of HO-1 human metastatic melanoma cells. J
Cell Physiol. 226:194–204. 2011. View Article : Google Scholar
|
|
12
|
Uddin S, Ahmed M, Hussain A, Abubaker J,
Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan
Z, Bavi P, Siraj AK and Al-Kuraya KS: Genome-wide expression
analysis of Middle Eastern colorectal cancer reveals FOXM1 as a
novel target for cancer therapy. Am J Pathol. 178:537–547. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bektas N1, Haaf At, Veeck J, et al: Tight
correlation between expression of the Forkhead transcription factor
FOXMl and HER2 in human breast cancer. BMC Cancer. 8:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia L1, Mo P, Huang W, Zhang L, Wang Y,
Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Chen Z, Hu H, Fan D, Nie Y
and Wu K: The TNF-α/ROS/HIF-1-induced upregulation of FoxMI
expression promotes HCC proliferation and resistance to apoptosis.
Carcinogenesis. 33:2250–2259. 2012.
|
|
15
|
Wang Y1, Wen L, Zhao SH, Ai ZH, Guo JZ and
Liu WC: FoxM1 expression is significantly associated with
cisplatin-based chemotherapy resistance and poor prognosis in
advanced non-small cell lung cancer patients. Lung Cancer.
79:173–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang IC, Chen YJ, Hughes D, et al:
Forkhead box M1 regulates the transcriptional network of genes
essential for mitotic progression and genes encoding the SCF
(Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmad A, Wang Z, Kong D, et al: FoxM1
down-regulation leads to inhibition of proliferation, migration and
invasion of breast cancer cells through the modulation of
extra-cellular matrix degrading factors. Breast Cancer Res Treat.
122:337–346. 2010. View Article : Google Scholar
|
|
18
|
Priller M, Pöschl J, Abrão L, et al:
Expression of FoxM1 is required for the proliferation of
medulloblastoma cells and indicates worse survival of patients.
Clin Cancer Res. 17:6791–6801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Q, Zhang N, Jia Z, et al: Critical role
and regulation of transcription factor FoxM1 in human gastric
cancer angiogenesis and progression. Cancer Res. 69:3501–3509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karadedou CT, Gomes AR, Chen J, et al:
FOXO3a represses VEGF expression through FOXM1-dependent and
-independent mechanisms in breast cancer. Oncogene. 31:1845–1858.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dai B, Kang SH, Gong W, et al: Aberrant
FoxM1B expression increases matrix metalloproteinase-2
transcription and enhances the invasion of glioma cells. Oncogene.
26:6212–6219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balli D, Ustiyan V, Zhang Y, et al: Foxm1
transcription factor is required for lung fibrosis and
epithelial-to-mesenchymal transition. EMBO J. 32:231–244. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang C, Chen H, Tan G, et al: FOXM1
promotes the epithelial to mesenchymal transition by stimulating
the transcription of Slug in human breast cancer. Cancer Lett.
340:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Del Barco S, Vazquez-Martin A, Cufi S, et
al: Metformin: multi-faceted protection against cancer. Oncotarget.
2:896–917. 2011.PubMed/NCBI
|
|
25
|
Hadad SM, Hardie DG, Appleyard V and
Thompson AM: Effects of metformin on breast cancer cell
proliferation, the AMPK pathway and the cell cycle. Clin Transl
Oncol. Dec 12–2013.(Epub ahead of print).
|
|
26
|
He SY, Shen HW, Xu L, et al: FOXM1
promotes tumor cell invasion and correlates with poor prognosis in
early-stage cervical cancer. Gynecol Oncol. 127:601–610. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu K, Yin X, Weng T, et al: Targeting WW
domains linker of HECT-type ubiquitin ligase Smurf1 for activation
by CKIP-1. Nat Cell Biol. 10:994–1002. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yung MMCD, Liu VW, Yao KM and Ngan HY:
Activation of AMPK inhibits cervical cancer cell growth through AKT
FOXO3a FOXM1 signaling cascade. BMC Cancer. 13:3272013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hugo H, Ackland ML, Blick T, et al:
Epithelial-mesenchymal and mesenchymal-epithelial transitions in
carcinoma progression. J Cell Physiol. 213:374–383. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Korver W, Roose J, Heinen K, et al: The
human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and
promoter characterization. Genomics. 46:435–442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laoukili J, Stahl M and Medema RH: FoxM1:
at the crossroads of ageing and cancer. Biochim Biophys Acta.
1775:92–102. 2007.PubMed/NCBI
|
|
32
|
Nieto MA: Epithelial-mesenchymal
transitions in development and disease: old views and new
perspectives. Int J Dev Biol. 53:1541–1547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Slabáková E, Pernicová Z, Slavíčková E,
Staršíchová A, Kozubík A and Souček K: TGF-β1-induced EMT of
non-transformed prostate hyperplasia cells is characterized by
early induction of SNAI2/Slug. Prostate. 71:1332–1343. 2011.
|
|
35
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013.
|
|
36
|
Saitoh M and Miyazawa K: Transcriptional
and post-transcriptional regulation in TGF-β-mediated
epithelial-mesenchymal transition. J Biochem. 151:563–571.
2012.
|
|
37
|
Lin T, Ponn A, Hu X, Law BK and Lu J:
Requirement of the histone demethylase LSD1 in Snai1-mediated
transcriptional repression during epithelial-mesenchymal
transition. Oncogene. 29:4896–4904. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gorbachinsky I, Akpinar H and Assimos DG:
Metabolic syndrome and urologic diseases. Rev Urol. 12:e157–e180.
2010.PubMed/NCBI
|
|
39
|
Parsons JK, Carter HB, Partin AW, et al:
Metabolic factors associated with benign prostatic hyperplasia. J
Clin Endocrinol Metab. 91:2562–2568. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jalving M, Gietema JA, Lefrandt JD, et al:
Metformin: taking away the candy for cancer? Eur J Cancer.
46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cufi S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to-mesenchymal transition
(EMT): from cancer stem cells to aging-associated fibrosis. Cell
Cycle. 9:4461–4468. 2010.
|
